argenx announces results of Annual General Meeting of Shareholders
May 10 2022 - 5:30PM
May 10, 2022
Breda, the Netherlands
– argenx SE (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that all proposed resolutions at its Annual General Meeting of
Shareholders, held today at 10:00 a.m. CEST, were duly passed.
As part of the approved resolutions:
- The company's
annual report and annual accounts for the financial year ending
December 31, 2021, were approved;
- The advisory
vote on the company's remuneration report for the financial year
ending December 31, 2021, was passed;
- Tim Van
Hauwermeiren has been re-appointed as executive director to the
Board of Directors for a term of four (4) years;
- Peter Verhaeghe
has been re-appointed as non-executive director to the Board of
Directors for a term of two (2) years;
- Jim Daly has
been re-appointed as non-executive director to the Board of
Directors for a term of four (4) years;
- Werner Lanthaler
has been re-appointed as non-executive director to the Board of
Directors for a term of two (2) years;
- The Board of
Directors was authorized to issue shares and grant rights to
subscribe for shares in the share capital of the company for up to
10% of the outstanding share capital at the date of the meeting and
for a period of 18 months from the meeting;
- The proposed
amendments to the articles of association have been approved;
and
- Deloitte
Accountants B.V. has been appointed as the Company's auditor for
the 2022 financial year.
The results of the votes and all documents
relating to the shareholders’ meeting will be available on the
Company’s website at
www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune
diseases. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate
immunology breakthroughs into a world-class portfolio of novel
antibody-based medicines. argenx developed and is commercializing
the first-and-only approved neonatal Fc receptor (FcRn) blocker in
the U.S. and Japan. The Company is evaluating efgartigimod in
multiple serious autoimmune diseases and advancing several earlier
stage experimental medicines within its therapeutic franchises. For
more information, visit www.argenx.com and follow us on
LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:Kelsey Kirkkkirk@argenx.com
Investors:Beth
DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Argen X (EU:ARGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Argen X (EU:ARGX)
Historical Stock Chart
From Sep 2023 to Sep 2024